v3.26.3
Consolidated Statements of Comprehensive (Loss) Income - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Statement of Other Comprehensive Income [Abstract]        
Net income $ 12,306 $ 18,132 $ 159,920 $ 78,360
Less: Net income attributable to non-controlling interests (19,762) (15,763) (47,458) (41,379)
Net (loss) income attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interests (7,456) 2,369 112,462 36,981
Accretion of redeemable non-controlling interests (14,239) 0 (14,239) 0
Net (loss) income attributable to Amneal Pharmaceuticals, Inc. (21,695) 2,369 98,223 36,981
Other comprehensive (loss) income:        
Foreign currency translation adjustments arising during the period (3,428) (9,088) (13,332) (15,648)
Unrealized gain (loss) on cash flow hedge, net of tax of $0 17,563 (3,526) 28,019 (23,011)
Reclassification of cash flow hedge to earnings, net of tax of $0 2,942 4,162 8,730 (1,714)
Other Comprehensive Income, Other, Net of Tax 505 0 4,228 0
Other comprehensive income (loss) attributable to Amneal Pharmaceuticals, Inc. 17,582 (8,452) 27,645 (40,373)
Comprehensive (loss) income attributable to Amneal Pharmaceuticals, Inc. $ (4,113) $ (6,083) $ 125,868 $ (3,392)